Premium
Identification of JAK2 V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera
Author(s) -
Ganly Peter,
Hanrahan Vickie,
Baker Bart,
Romeril Ken
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20721
Subject(s) - polycythemia vera , essential thrombocythemia , myelofibrosis , medicine , gastroenterology , ruxolitinib , polycythemia rubra vera , bone marrow
One hundred and forty four patients with a clinical indication of suspected polycythemia vera (PV), essential thrombocythemia, or idiopathic myelofibrosis were screened for JAK2 V617F and the mutation frequency was 47, 51, and 50%, respectively. Previous investigations enabled 42 of 66 patients with suspected PV to be definitively diagnosed either as PV according to WHO criteria or to have this diagnosis excluded. Ninety‐six percent of those with PV were JAK2 V617F , whereas all patients without PV did not have the mutation. Early screening of suspected PV patients for JAK2 V617F rapidly identifies nearly all those with PV without invasive or less specific conventional investigations. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.